Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05226455
Other study ID # VENTOGRAFT
Secondary ID 2021-000632-56
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date November 23, 2022
Est. completion date March 1, 2026

Study information

Verified date April 2024
Source Groupe Francophone des Myelodysplasies
Contact Fatiha CHERMAT
Phone 01 71 20 70 59
Email fatiha.chermat-ext@aphp.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Study to assess venetoclax + azacitidine and donor lymphocyte infusion (DLI) in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) with blasts < 30% in relapse after allohematopoietic stem cell transplantation (AHSCT).


Description:

A phase I-II study to assess venetoclax + azacitidine and donor lymphocyte infusion (DLI) in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) with blasts < 30% in relapse after allohematopoietic stem cell transplantation (AHSCT).


Recruitment information / eligibility

Status Recruiting
Enrollment 55
Est. completion date March 1, 2026
Est. primary completion date September 1, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Documented relapse of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) with marrow blasts < 30% (with white blood cells (WBC) < 15000/mm3), after allohematopoietic stem cell transplantation. Relapse of MDS or AML is defined as : - Return to pretreatment bone marrow blast percentage - Decrement of at least 50% from maximum remission 2. Age = 18 years. 3. Eastern Cooperative Oncology Group (ECOG) performance status = 2. 4. Patient must have adequate organ function: - Serum creatinine < 2 mg/dL or calculated creatinine clearance = 30 mL/min for patients with creatinine levels > 1.5 times Upper Limit of Normal - Serum total bilirubin = 2.5 times Upper Limit of Normal or direct bilirubin = Upper Limit of Normal for patients with total bilirubin levels = 2 mg/d - Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) = 2.5 times Upper Limit of Normal - Alkaline phosphatase = 5 times Upper Limit of Normal (if > 2.5 times Upper Limit of Normal, then liver fraction should be = 2.5 times Upper Limit of Normal). 5. Patient not refractory to platelet transfusions. 6. Female subject of childbearing potential must practice at least one protocol specified method of birth control, starting on Study Day 1 through at least 30 days after the last dose of venetoclax or 3 months after the last dose of azacitidine. Not being of childbearing potential is defined as: - Age > 55 years with no menses for 12 or more months without an alternative medical cause, or - Age = 55 years with no menses for 12 or more months without an alternative medical cause AND an Follicle Stimulating Hormone (FSH) level > 40 IU/L, or - Permanent surgical sterility (bilateral oophorectomy, bilateral salpingectomy or hysterectomy). 7. Female subjects of childbearing potential must have negative results for pregnancy test performed: - At Screening with a serum sample obtained within 14 days prior to the first study drug administration, and - Prior to dosing with urine sample obtained on Cycle 1 Day 1, if it has been > 7 days since obtaining the serum pregnancy test results. Female subjects who are not of childbearing potential at Screening do not require pregnancy testing. 8. Male subjects sexually active with female partner(s) of childbearing potential, must agree from first dose of study drug(s) through at least 30 days after the last dose of venetoclax or 3 months after the last dose of azacitidine, whichever is later, to practice the protocol specified contraception. 9. Patient is available for periodic blood sampling, study related assessments, and appropriate clinical management at the treating institution for the duration of the study. 10. Patient has the ability to understand and willingness to sign an informed consent form indicating the investigational nature of the study. 11. Patient is able to swallow capsules. Exclusion Criteria: 1. Patient has active and uncontrolled infection. 2. Patient has active acute or chronic Graft-versus-Host-Disease (GVHD). 3. Patient receives more than 1mg/kg/day prednisolone. 4. Patient has uncontrolled intercurrent illness or circumstances that could limit compliance with the study, including but not limited to the following: symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, pancreatitis, or psychiatric or social conditions that may interfere with patient compliance. 5. Patient is currently participating or has participated in a study with an investigational compound or device within 30 days of initial dosing with study drug. 6. Patient has known human immunodeficiency virus (HIV) infection or HIV-related malignancy. 7. Patient has clinically active hepatitis B or hepatitis C infection. 8. Patient has a known allergy or hypersensitivity to any component of venetoclax or azacitidine. 9. Patient with a "currently active" second malignancy, other than non-melanoma skin cancer and carcinoma in situ of the cervix, should not be enrolled. Patients are not considered to have a "currently active" malignancy if they have completed therapy for a prior malignancy, are disease free from prior malignancies for > 2 years or are considered by their physician to be at less than 30% risk of relapse. 10. Patient has received growth factors such as erythropoietin alfa (EPO) or granulocyte colony-stimulating factor (G-CSF) or has received non cytotoxic agents (including low dose oral chemotherapy) in the 30 days before inclusion. In case of previous cytotoxic treatment, an interval of 3 months is required. 11. Patient is on any systemic steroids that have not been stabilized to the equivalent of = 10 mg/day prednisone during the 4 weeks prior to the start of the study drugs. 12. Patients with clinical evidence of Central Nervous System leukemia. 13. Patient has a history of Gastrointestinal surgery or other procedures that might interfere with the absorption or swallowing of the study drugs. 14. Subject has received strong or moderate CYP3A (Cytochrome P450, family 3, subfamily A) inhibitors within 3 days prior to the first dose of study drug. 15. Patient is unable to take and/or tolerate oral medications on a continuous basis. 16. Patient is pregnant or breastfeeding within the projected duration of the study. 17. Subject has a malabsorption syndrome or other condition that precludes an enteral route of administration. 18. Absence of social security.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
venetoclax + azacitidine +/- donor lymphocyte infusion
Venetoclax will be given once daily orally on days 1 to 14 for all cycles. Venetoclax + azacitidine +/- donor lymphocyte infusion (12 cycles maximum)

Locations

Country Name City State
France CHU d'Amiens Picardie - Site sud Amiens
France CHU d'Angers Angers
France CHU de Grenoble Grenoble
France Hôpital Dupuytren Limoges
France Hôpital Saint-Eloi Montpellier
France CHU Hôtel Dieu Nantes
France Hôpital l'Archet I Nice
France Hôpital Saint louis Paris
France CHU de Haut-Lévèque Pessac
France Centre Hospitalier Lyon-Sud Pierre-Bénite
France Centre Henri Becquerel Rouen
France Institut de Cancérologie de la Loire Lucien Neuwirth Saint-Priest-en-Jarez
France IUCT Oncopole Toulouse
France Hôpital Brabois VandÅ“uvre-lès-Nancy

Sponsors (2)

Lead Sponsor Collaborator
Groupe Francophone des Myelodysplasies AbbVie

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Other Correlation between patient overall mutational status before and after treatment Mutational analysis performed by NGS (next-generation sequencing) at screening and then at each protocol evaluation (post 4, 6 and 8 cycles of venetoclax + azacitidine and at end of study) At 42 months (at end of study)
Other Prognostic impact of Minimal Residual Disease (MRD) on outcome Minimal Residual Disease (MRD) assessment by flow cytometry and allelic variant frequency (VAF) of baseline mutations At 42 months (at end of study)
Primary Phase I: Dose-finding study Evaluation of Dose-limiting toxicity (DLT) to determine the optimal dose level in terms of both toxicity and safety for venetoclax + azacitidine At the end of cycle 1 of venetoclax + azacitidine (each cycle is 28 days)
Primary Phase II: Overall improvement rate of venetoclax + azacitidine +/- DLI Response assessment performed according to modified IWG (International Working Group) 2006 criteria for myelodysplastic syndrome and to European Leukemia Net criteria for acute myeloid leukemia After 8 cycles of venetoclax + azacitidine (each cycle is 28 days)
Secondary Toxicity assessment Adverse events analyzed by frequency, NCI CTCAE 5.0 grade, and causality At 42 months (at end of study)
Secondary Graft-versus-Host-Disease (GVHD) rate Acute and chronic graft-versus-host-disease (GVHD) rate assessment (graft-versus-host events analyzed by frequency and grade) At 42 months (at end of study)
Secondary Duration of response Duration of response defined as time from the date of the first observed response (complete or partial) to the date of first subsequent documented disease progression or relapse or death At 42 months (at end of study)
Secondary Overall survival Overall Survival defined as time from the date of the first dose of venetoclax to the date of death or end of study At 42 months (at end of study)
Secondary Progression-free survival Progression-free Survival for patients with at least a partial response defined as time from the date of the first dose of venetoclax to the date of the first documented disease progression or relapse or death At 42 months (at end of study)
Secondary Event-free survival Event-free Survival defined as time from the date of the first dose of venetoclax to the date of earliest disease progression or death At 42 months (at end of study)
See also
  Status Clinical Trial Phase
Completed NCT03118466 - Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia Phase 2
Not yet recruiting NCT06313437 - Revumenib in Combination With 7+3 + Midostaurin in AML Phase 1
Withdrawn NCT03444649 - Epacadostat, Idarubicin and Cytarabine (EIC) in AML Phase 1
Withdrawn NCT02905994 - Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia Phase 1
Recruiting NCT02261779 - Phase I/II Trial of ATRA and TCP in Patients With Relapsed or Refractory AML and no Intensive Treatment is Possible Phase 1/Phase 2
Completed NCT00333190 - CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation N/A
Completed NCT00246649 - Stem Cell Transplant With Specially Treated Cells in Treating Patients With Acute Leukemia N/A
Terminated NCT04079738 - Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib Phase 1/Phase 2
Completed NCT03466320 - DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2 Phase 1/Phase 2
Withdrawn NCT03138395 - iCare3: Monitoring Circulating Cancer DNA After Chemotherapy in MDS and AML N/A
Terminated NCT01570465 - Prospective Study on Severe Infections on Acute Myeloid Leukemia (AML) Patients
Completed NCT04443751 - A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Phase 1
Terminated NCT03761069 - Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias Phase 1
Completed NCT02631993 - Photochemotherapy and Graft-versus-leukemia in Acute-leukemia N/A
Completed NCT02575963 - Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients Phase 1/Phase 2
Completed NCT00780598 - Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML Phase 2
Completed NCT00863148 - Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL) Phase 2
Completed NCT00542971 - Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006) Phase 1/Phase 2
Completed NCT00761449 - Lenalidomide in High-risk MDS and AML With Del(5q) or Monosomy 5 Phase 2
Terminated NCT00176930 - Stem Cell Transplant for Hematological Malignancy N/A